Futoshi Nara

USPTO Granted Patents = 11 (Patent Applications = 1)

EPO Patents = 1 (Patent Applications = 1)

Average Co-Inventor Count = 4.8

ph-index = 4

Forward Citations = 39(Granted Patents)

Location History:

Chiba, JP (2010 - 2011)
Yachiyo, JP (2004 - 2012)
Tokyo, JP (2015 - 2017)

Company Filing History:

6 out of 613

Sankyo Company, Limited

patents

5 out of 445

Daiichi Sankyo Company, Limited

patents

Years Active: 2004-2017

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9598476 - Nucleic acid molecules encoding muteins of human tear lipocalin which bind PCSK9 (2017-03-21),

2. 9150629 - Human tear lipocalins which bind PCSK9 and methods of use thereof (2015-10-06),

3. 8101650 - Method for treating a immunology-related disease (2012-01-24),

4. 8071300 - Drug-phosphorylating enzyme (2011-12-06),

5. 8067396 - Amino alcohol compounds or phosphonic acid derivatives thereof (2011-11-29),

6. 7910617 - Method for suppressing the number of peripheral blood lymphocytes using an amino alcohol compound (2011-03-22),

7. 7687491 - Heterocyclic compound (2010-03-30),

8. 7638551 - Amino alcohol compounds or phosphonic acid derivatives thereof (2009-12-29),

9. 7199150 - Amino alcohol compounds (2007-04-03),

10. 6964976 - Amino alcohol derivatives (2005-11-15),

11. 6723745 - Amino alcohol derivatives (2004-04-20),

Title: The Innovative Journey of Futoshi Nara: A Leading Inventor in Biotech

Introduction: Futoshi Nara, based in Yachiyo, Japan, is a prolific inventor with an impressive portfolio of 11 patents. His work primarily focuses on biotechnological innovations, particularly in the field of proteins and nucleic acid molecules. His contributions have been influential in scientific advancements and therapeutic applications.

Latest Patents: Futoshi Nara’s latest patents include groundbreaking research on "Nucleic acid molecules encoding muteins of human tear lipocalin which bind PCSK9." This disclosure involves novel lipocalin muteins that interact with PCSK9, along with the corresponding nucleic acid molecules and methods for producing these lipocalin muteins. Additionally, he has patented "Human tear lipocalins which bind PCSK9 and methods of use thereof," which elaborates on similar concepts and applications, underscoring the significance of his innovations in addressing medical challenges.

Career Highlights: Throughout his distinguished career, Futoshi Nara has worked with reputable organizations such as Sankyo Company, Limited and Daiichi Sankyo Company, Limited. His tenure at these companies has enabled him to contribute substantially to the development of therapeutic solutions, focusing on the modulation of lipocalins for medical applications.

Collaborations: Collaboration has played a key role in Futoshi Nara's success. He has worked alongside esteemed colleagues including Takahide Nishi and Takaichi Shimozato. Their combined expertise has been essential in advancing their shared research interests and driving innovation in their projects.

Conclusion: Futoshi Nara's innovative spirit and dedication to research have established him as a prominent figure in the field of biotechnology. His patents highlight not only his expertise but also his commitment to developing solutions that have the potential to transform medical science. As he continues to explore new avenues of research, Futoshi Nara remains an inspiring inventor whose work will undoubtedly influence future innovations in biochemistry and therapeutics.

This text is generated by artificial intelligence and may not be accurate.